Previously, we identified SETD2 LOF mutations in approximately 6% of acute myeloid leukemia (AML) and acute lymphoid leukemia (ALL), with a particularly high prevalence of over 20% in mixed lineage leukemia-rearranged (MLL-r) leukemia [5]. This evidence concerns the gene SETD2 and leukemia.